Alumag

Quick links to important sections

Alumag

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Alumag

This overview defines Alumag, its composition, classification, and general purpose, based on its primary active component, Aluminum Hydroxide.

Property Description
Active ingredient Aluminum Hydroxide, often combined with Magnesium Hydroxide
Form Suspension (oral liquid) or Chewable tablet
Pharmacological class Antacid, Acid Neutraliser
Common use Relief from gastric hyperacidity and heartburn
Origin Synthetic/Inorganic salt

What Type of Medicine is Alumag? (Identity and Classification)

Alumag is an oral medication classified as an Antacid and Acid Neutraliser, designed to manage the symptoms caused by excessive stomach acid. The product is most commonly a multicomponent medicinal preparation, combining Aluminum Hydroxide with Magnesium Hydroxide for a balanced effect. This formulation strategy is a common and established method for effective acid relief. The core principle remains providing immediate, direct relief from gastrointestinal discomfort, which is a recognized benefit of this pharmacological class.

As a member of the antacid group, Alumag’s fundamental action is direct and localized. The preparation is available in several dosage forms, including a liquid suspension or a chewable tablet, and is taken via the oral route of administration. Its over-the-counter (OTC) status in many regions underscores its primary positioning for self-managed, intermittent episodes of mild gastric hyperacidity.


Composition and Origin: The Role of Inorganic Salts

The active core of Alumag is defined by the synthetic inorganic salts, Aluminum Hydroxide (Al(OH)3) and Magnesium Hydroxide (Mg(OH)2), both of which function as basic compounds. Combined aluminum and magnesium antacids are utilized for neutralizing gastric acid. This dual-salt approach is a standard pharmacological application used to enhance the patient experience.

Aluminum Hydroxide is the primary agent responsible for consuming excess hydrochloric acid in the stomach, while the Magnesium Hydroxide component is included to counteract the constipating effects often associated with aluminum-only preparations. This crucial composition feature differentiates it from single-agent antacids, ensuring the medication delivers its acid-neutralizing effect while optimizing patient tolerance.


General Purpose: Relieving Gastric Hyperacidity

The general purpose of Alumag is to alleviate the symptoms of gastric hyperacidity, which describes the state of having abnormally high acid levels in the stomach. A typical scenario involves the occasional discomfort or irritation known as heartburn that occurs after a large or rich meal. By means of chemical neutralization, the active ingredients quickly raise the pH of the gastric contents. This action provides relief for common symptoms such as heartburn, acid indigestion, and general discomfort associated with an upset stomach, all resulting from the presence of excess acid and active pepsin.

Regulatory References

  1. Aluminum Hydroxide and Magnesium Hydroxide: MedlinePlus Drug Information

What side effects are possible with Alumag?

Possible Side Effects and Safety Information: Alumag

This summary outlines the officially documented side effects and safety considerations for Alumag (a combination of Aluminum Hydroxide and Magnesium Hydroxide), strictly based on governmental regulatory documents.


Adverse Reaction Scope

The most common adverse reactions affect the Gastrointestinal System. The formulation aims to balance the effects of its components, where Magnesium Hydroxide can cause diarrhea and Aluminum Hydroxide can cause constipation. These effects are generally classified as Uncommon.

Serious and Clinically Significant Adverse Reactions primarily involve metabolic and electrolyte disturbances, notably Hypermagnesemia and Hyperaluminemia. These risks are severely amplified in patients with renal impairment, which is a contraindication in severe cases due to the potential for systemic toxicity, encephalopathy, and worsening bone disorders. Long-term use of the aluminum component may lead to Phosphate Depletion (hypophosphatemia), which can increase bone resorption and potentially cause osteomalacia.

Rarely reported reactions of Hypersensitivity, including angioedema and anaphylaxis, have been documented.


Safety Considerations and Restrictions

Population-Specific Considerations:

  • Severe Renal Impairment: Contraindicated due to the significant risk of accumulation and toxicity of both aluminum and magnesium.
  • Elderly/Children: Should be used with caution, particularly in the presence of reduced kidney function or conditions predisposing to bowel hypomotility.

Safety-Related Limitations:

  • Duration of Use: The product is generally not intended for prolonged, continuous use; long-term therapy may necessitate monitoring of phosphate and kidney function.
  • Drug Interactions: Alumag may significantly interfere with the absorption of many other orally administered medicines, necessitating a separation in dosing schedules.

Overdose and Emergency Response

Overdose Scope

Domain Official Regulatory Statement
Documented Overdose Presentations Acute presentations include diarrhoea, abdominal pain, and vomiting. Chronic or severe presentations are marked by hypermagnesemia, hypophosphatemia, hyporeflexia, and CNS depression.
Physiological Systems Affected Gastrointestinal (intestinal obstruction, ileus), Cardiovascular (cardiac arrest), Respiratory (respiratory paralysis), and Central Nervous System (encephalopathy, coma).
Dose-Related or Exposure-Related Factors Long-term use or excessive doses are associated with the risk of aluminum accumulation and phosphate depletion. Large doses may induce intestinal obstruction.
Population-Specific Overdose Notes Patients with advanced kidney disease are at the highest risk for accumulation toxicity. The elderly are cited as having a higher risk for ileus.
Emergency-Response Statements Seek emergency medical attention. Consult a doctor if more than the recommended dose is taken. Contact a poison control center.
When immediate medical help is required Get medical care right away. Go to a hospital straight away if symptoms are severe or suggest bowel obstruction.

Overdose Classifications (High-Level)

Classification Aspect Official Regulatory Statement
Severity Classification Overdose severity ranges from common, mild acute GI effects to severe, potentially life-threatening effects, specifically cardiac arrest or respiratory paralysis associated with severe hypermagnesemia.
Overdose-Context Constraints Acute overdose management includes symptomatic and supportive treatment. Treatment for hypermagnesemia is specifically described as the administration of IV Calcium Gluconate.

Resulting Overdose Structure

Official Overdose Statements:

  • Overdose may present with common gastrointestinal symptoms, including diarrhoea, vomiting, and abdominal pain.
  • Severe overdose, particularly when kidney function is impaired, can result in the accumulation of magnesium (hypermagnesemia) leading to hyporeflexia, CNS depression, and potentially cardiac arrest or respiratory paralysis.
  • Accumulation of aluminum from long-term high-dose use carries a documented risk of chronic toxicities, including encephalopathy and microcytic anaemia.
  • Management involves discontinuing the medication and providing supportive measures such as rehydration and forced diuresis; in cases of severe renal impairment, haemodialysis is required.
  • Individuals must seek emergency medical attention or consult a doctor if more than the recommended dose has been taken or if severe symptoms are experienced.

Connection to the overall overdose profile (2–4 sentences): Regulatory documents define the overdose profile primarily through the risks of cation accumulation (hypermagnesemia, hyperaluminemia) which pose a greater threat than the initial acute gastrointestinal effects. The profile specifically requires immediate attention when accumulation toxicity is suspected, particularly in patients with pre-existing renal impairment, or when severe outcomes such as CNS depression or intestinal obstruction are manifested. These documents explicitly mandate the immediate seeking of medical help, often directing the use of specific procedures like IV Calcium Gluconate for severe magnesium effects and dialysis for chronic accumulation, thereby setting the precise boundaries for emergency intervention.

Therapeutic Uses of Alumag

What Alumag Treats: Main Uses and Benefits

Alumag is commonly used to help with symptomatic relief for the burning and irritation associated with gastric hyperacidity, applied in contexts involving certain distressing symptoms like heartburn and acid indigestion. This medication is relevant for use in conditions characterized by periods of heightened symptoms, including acute discomfort related to Gastritis, Esophagitis, GERD, and Peptic Ulcer Disease.

The medication is generally applied during intermittent episodes or acute flare-ups of symptoms to help ease the impact of sudden discomfort and sour stomach. It plays a role in managing manifestations that often accompany acid issues, such as epigastric pain, belching, and general feelings of dyspepsia. By providing additional symptomatic support, it may assist with general well-being during symptomatic phases and contributes to easing distress during periods of heightened symptoms.

“The primary goal of this antacid is to provide supportive relief when symptoms interfere with routine activities.”

Quick Fact: Relief for Heartburn and Indigestion

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Alumag?

This section defines the population eligibility for Alumag (Aluminum/Magnesium Hydroxide antacids) based strictly on governmental regulatory labeling. Eligibility is categorized by formal contraindications, age restrictions, and specific health conditions.


Populations Who Must Not Use Alumag (Contraindications)

Official documents state that the medicine is contraindicated in several groups to prevent toxicity or complications:

  • Severe Renal Insufficiency/Kidney Failure: Must not be used due to the significant risk of aluminum and magnesium accumulation.
  • Hypophosphatemia: Contraindicated due to the potential for the aluminum component to bind phosphate.
  • Bowel Obstruction (Ileus): Use is prohibited due to the risk of aggravating or triggering a blockage.

Eligibility by Age and Organ Status

Population Group Eligibility Status (Regulatory Labeling)
Adults Generally permitted under standard conditions.
Older Adults (Geriatric) Use requires caution due to potential age-related decline in kidney function.
Children Not recommended below specific age thresholds (e.g., under 14 years in some regions).
Moderate Renal Impairment Restricted use; prolonged high-dose use is advised against.
Pregnancy Avoid prolonged or high-dose use; consult labeling for specific trimester guidance.
Lactation (Breastfeeding) Generally considered compatible at recommended doses.

Eligibility is also restricted for severely debilitated patients and those with known hypersensitivity to the ingredients.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Alumag (Aluminum Hydroxide/Magnesium Hydroxide) exhibits a specific interaction profile primarily defined by its non-systemic antacid properties, as documented in regulatory information. The most significant interactions are pharmacokinetic, resulting in a reduced oral absorption of co-administered medicines.

Documented Exposure-Altering Interactions

Co-administration with Alumag is officially documented to decrease the plasma concentration (exposure) of several medicines due to chelation or pH alteration in the stomach. These interacting substances include Tetracycline and Quinolone antibiotics, as well as the thyroid hormone Levothyroxine.

Interaction Type Interacting Substance Official Outcome
Pharmacokinetic Tetracyclines, Quinolones Reduced systemic exposure (Decreased absorption)
Pharmacokinetic Levothyroxine Reduced therapeutic efficacy (Decreased absorption)
Pharmacodynamic Agents Affecting Bowel Motility Alteration of effects on gastrointestinal function

Mandatory Timing Separation

To mitigate the documented risk of decreased exposure for critical systemic drugs, official labeling mandates timing separation. Medicines whose absorption is reduced by Alumag must be administered at least 2 to 4 hours before or after the antacid dose. This procedural constraint is required to maintain the effectiveness of the co-administered drug. Additionally, Aluminum Hydroxide formally interacts with and binds Dietary Phosphates, which can lead to phosphate depletion.

Mechanism of Action

The action of Alumag (Aluminum Hydroxide/Magnesium Hydroxide) is defined by a rapid, local chemical neutralization mechanism within the stomach lumen, operating independent of cellular signaling pathways.

Direct Chemical Neutralization of Acid and Pepsin

Its core mechanism involves the stoichiometric reaction of the basic salts with the Hydrochloric Acid ( HCl) and Hydrogen Ions ( H^+) present in the stomach. This chemical interaction consumes the acid, resulting in a substantial and immediate rise in the local pH environment, which is a determinant of the pH increase kinetics. As a physiological consequence, this pH elevation effectively suppresses the corrosive activity of the proteolytic enzyme Pepsin, which is only functional in highly acidic conditions.

Mechanistic Balancing of Gastrointestinal Motility

The dual-salt formulation relies on a synergistic mechanism to manage downstream physiological processes. Magnesium Hydroxide tends to accelerate the transit of stomach contents, while Aluminum Hydroxide has a tendency to slow it. This mechanistic counter-balancing prevents wide deviations in gastrointestinal motility, which is a functional consequence of the combined mechanistic design.

Dosage and Administration Information

Administration Guidelines for Alumag

Alumag, the combination of Aluminum Hydroxide and Magnesium Hydroxide, must be administered orally. Adherence to standard dosing and preparation instructions is required for proper use.

Dosage and Schedule

Dosage Form Standard Dose (Adults and children 12+ years) Frequency and Timing
Oral Suspension 10 mL to 20 mL 4 times a day, or after meals and at bedtime
Chewable Tablets 1 to 4 tablets 4 times a day, or after meals and at bedtime

Preparation and Limits

  • Suspension: The liquid must be shaken well before each use to ensure proper mixing of ingredients.
  • Tablets: Chewable tablets must be chewed thoroughly before swallowing, often followed by a full glass of water.
  • Maximum Dose: Do not take more than 80 mL (or the equivalent tablet dose) within a 24-hour period.
  • Duration: Do not use the maximum dose for more than 2 weeks (14 days) unless specifically directed by a healthcare provider.
  • Missed Dose: If the medicine is taken on a regular schedule and a dose is missed, take it as soon as remembered; however, do not double the dose to make up for the skipped one.
  • Pediatrics: Dosing for children under 12 years should only be done under the advice and supervision of a physician.

Recent Clinical Evidence

Alumag: Recent Clinical Evidence

Evidence for use in Mild, Intermittent Heartburn (GERD)

Research explored its use in heartburn and is primarily found in short-term randomized controlled trials (RCTs) and older comparative studies. This research examined how symptoms change over time and focused on outcomes related to physical discomfort, such as the intensity and frequency of patient-reported heartburn. The populations studied were typically adults experiencing uncomplicated, episodic manifestations of acid reflux or general stomach discomfort.

Studies monitored how symptoms evolved in the observed populations immediately following the administration of the compound. Research highlights changes measured during these short study periods, with some trials describing patterns related to a temporary shift in the stomach's acid level. Findings contribute to understanding symptom patterns over very short durations.

However, the evidence remains limited and heterogeneous. Follow-up durations were limited, often covering only single doses or a few days of use. Long-term outcomes, such as sustained symptom control, are not well characterized. Comparative evidence is lacking against newer treatments, and research provides limited insight for individuals with more severe or complicated conditions.

Evidence for use in Phosphate Binding in Kidney Disease

Alumag was evaluated in studies for its role in the management of high phosphate levels (hyperphosphatemia) in individuals with Chronic Kidney Disease (CKD). The research examined outcomes related to systemic or functional imbalance, specifically monitoring changes in serum phosphate levels and the calcium-phosphate product. These trials were often older cohort studies that studied patients with conditions involving periods of heightened symptoms related to kidney disease.

Studies monitored the compound in the digestive tract. Data show patterns related to phosphate level measurements during the study period. Research also described patterns related to the systemic absorption of aluminum, which was monitored alongside the primary lab outcomes. The evidence contributes to the broader evidence landscape but is often based on historical data.

The certainty remains low regarding the impact of the compound on key long-term clinical outcomes. The results apply primarily to the populations studied—adults with ESRD—and the data for certain subgroups remain insufficient. Comparative evidence is lacking from recent large-scale trials against current non-aluminum phosphate binders.

Key Studies & References Phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease: an overview of the literature

Frequently Asked Questions (FAQ)

Common questions about Alumag (FAQ)


Q: How quickly does Alumag start to work after taking it?

A: Official regulatory documents describe Alumag as having a rapid, local chemical neutralization mechanism. This action is designed to quickly interact with acid in the stomach, resulting in an immediate rise in the local pH environment.


Q: What is the typical duration of Alumag's effects?

A: Studies and evidence examining the use of this compound in conditions like heartburn have focused on outcomes measured over short periods. This indicates that the medicine’s acid-neutralizing effects are generally temporary and of short duration.


Q: Can Alumag be taken long-term?

A: Official administration guidelines state that the maximum recommended dose is generally not intended for continuous use longer than two weeks (14 days). The product is generally not intended for chronic, long-term use. Prolonged use may require monitoring of the body's phosphate levels and kidney function.


Q: Does Alumag cause drowsiness or affect alertness?

A: Drowsiness is not listed in the regulatory documents as a common or direct side effect of Alumag. However, severe drowsiness, confusion, or altered mental status are symptoms associated with hypermagnesemia, which is a serious adverse reaction linked primarily to use in people with pre-existing kidney problems.


Q: Does Alumag interact with alcohol?

A: Regulatory safety information does not describe a direct interaction between Alumag and alcohol. However, regulatory information suggests that individuals who consume alcohol frequently discuss the use of this product with a healthcare provider.


Q: Are there specific foods that should be avoided while using Alumag?

A: The Aluminum Hydroxide component is known to interact with and bind to dietary phosphates. Additionally, the use of aluminum-containing compounds in individuals with kidney impairment is associated with regulatory guidance concerning foods and drinks containing citrate (such as citrus fruits and certain soft drinks).


Q: Why are there different strengths of Alumag available?

A: Official regulatory information on dosages confirms that the medicine is available in various forms and concentrations. These varied strengths are made available to accommodate different dosage requirements for adults, offering options for the amount of active ingredients delivered.


Q: Does Alumag affect my ability to fall asleep?

A: Effects on sleep are not listed as common side effects in the official documentation. However, serious systemic effects like hypermagnesemia, which are rare and usually linked to kidney impairment, can be associated with deep sleep or changes in mental state.


Q: Is Alumag the same as other similar-sounding medicines?

A: Alumag is the name given to the combination of Aluminum Hydroxide and Magnesium Hydroxide. Other medicines that sound similar may contain different active components, such as calcium carbonate, or may include additional ingredients like anti-gas agents.


Q: Can Alumag be crushed or split if a person has trouble swallowing?

A: Official administration instructions state that chewable tablets must be chewed thoroughly before swallowing. Regulatory guidelines do not provide instructions for, nor permit, the crushing or splitting of tablets. The liquid suspension form is available for those who have trouble swallowing solid dosage forms.


Q: What is the physical appearance of the Alumag pill/tablet?

A: The specific regulatory labeling for medicines includes descriptions of the dosage form, such as its shape (e.g., round or oval), color, and size. These details are used for official identification, but they can vary depending on the product’s specific manufacturer and formulation.


Q: What is the meaning of the numbers or letters imprinted on the Alumag tablet?

A: The numbers and letters imprinted on tablets are official identification codes required by regulatory bodies. These codes help identify the drug's active ingredients, its manufacturer, and its specific dosage strength.


Q: Does Alumag have a noticeable taste or smell?

A: The active ingredients themselves are inorganic salts that are generally odorless. However, liquid formulations of the medicine contain inactive ingredients, such as flavoring agents, that are added to adjust the taste.


Q: Does Alumag interact with caffeine?

A: Official drug interaction information generally notes no direct interaction between Alumag and caffeine when taken alone. However, Alumag may interact with certain nonprescription pain relievers that contain caffeine, often by affecting their absorption.


Q: Is Alumag approved in countries outside the US?

A: The components of Alumag (Aluminum Hydroxide and Magnesium Hydroxide) are classified as antacids and are recognized by drug agencies worldwide. They are widely available in many countries across the globe, though often marketed under different brand names.


Q: Are the side effects of Alumag reversible?

A: The most commonly reported adverse reactions, such as changes in bowel movements (diarrhea or constipation), are typically mild and reversible once the use of the medicine is stopped or adjusted. Serious systemic effects, while rare, are generally reversible with appropriate medical intervention.


Q: Are there different brand names for the same Alumag formulation?

A: Yes. Regulatory documentation confirms that the specific combination of Aluminum Hydroxide and Magnesium Hydroxide is sold under numerous different brand names, in addition to being available as generic formulations.


Q: Is Alumag addictive or habit-forming?

A: Alumag is an antacid and is not classified as a controlled substance under regulatory scheduling acts. Official information indicates that this product is not known to be addictive or habit-forming.


Q: Does Alumag interact with herbal teas or remedies?

A: Regulatory guidance advises patients to inform their healthcare provider or pharmacist about all medications, supplements, and herbal products they are taking. This is because many substances can be affected by the changes Alumag causes in drug absorption.


Q: Can Alumag be used in people who have diabetes?

A: While Alumag itself is not a treatment for diabetes, it has the potential to interact with certain medications used to lower blood glucose, such as sulfonylureas, by reducing their absorption. A time separation between taking Alumag and these other medications may be required.


Q: Are there specific warnings about taking Alumag with over-the-counter pain relievers?

A: Yes. Official sources note that Alumag may interact with certain nonprescription pain relievers and anti-inflammatory drugs, such as aspirin and ibuprofen. This interaction can affect how much of the pain reliever is absorbed, and timing separation is often required to mitigate this risk.


Q: Do I need to get lab work done while taking Alumag?

A: Routine lab monitoring of phosphate and kidney function is generally not required for short-term use at recommended doses. However, such testing may be necessary for people on prolonged, continuous, or high-dose therapy, particularly if they have pre-existing kidney issues.


Q: Does Alumag affect blood pressure or heart rate?

A: The primary effects are on the digestive system. However, the serious adverse condition hypermagnesemia, linked to use in individuals with kidney impairment, can result in systemic effects such as irregular heartbeat (cardiac changes) or hypotension (low blood pressure).


Q: Is Alumag a controlled substance?

A: Regulatory sources confirm that Alumag, as an antacid, is not classified as a controlled substance under acts like the Controlled Substances Act.


Q: Does Alumag contain any ingredients that cause allergic reactions?

A: Official product information lists both active and inactive ingredients. These ingredients carry a rare risk of hypersensitivity reactions, and documented cases of severe allergic reactions, including angioedema and anaphylaxis, have been reported.


Q: Do people typically experience withdrawal effects when stopping Alumag?

A: As a non-systemic antacid that primarily works by direct chemical neutralization in the stomach, regulatory literature does not describe withdrawal symptoms as a characteristic effect when stopping this product.


Q: How does Alumag affect the liver?

A: The most common and serious adverse reactions described in the official safety profile are associated with the gastrointestinal system, kidneys, and metabolic processes. Liver-specific injury is not listed among the commonly or seriously reported adverse events.

How should Alumag be stored and disposed of?

The official regulatory profile for Alumag (Aluminum Hydroxide/Magnesium Hydroxide) specifies required conditions for storage and handling to maintain product stability and safety.

Storage Requirements

Alumag must be stored at Controlled Room Temperature, which is defined as 20 C to 25 C (68 F to 77 F). The medicine must be kept in its original container with the lid tightly closed to protect it from moisture and heat. It is a mandatory requirement to keep the product out of the reach of children. Liquid formulations, such as suspensions, must be protected from freezing to prevent product degradation.

Disposal Instructions

Unused or expired Alumag must be disposed of according to local regulations. Consumers should utilize authorized drug take-back programs when available. The product should not be disposed of in general household waste or flushed down a drain unless explicitly permitted by local pharmaceutical waste instructions.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Alumag found in:

A-Z Index: